Allergen-specific immunotherapy in children. Consensus document of the Association of Pediatric Allergologists and Immunologists of Russia (positional pаper)

The Document contains fundamental provisions regarding allergen specific immunotherapy in children.International clinical recommendations on the methodology were used, adapted for use in real practice.In the absence of international recommendations, the authors present the consensus opinion of the project participants, based on data from clinical studies in this area.At the moment, we bring to your attention a position paper on allergen specific immunotherapy in children, created by experts from the Association of Pediatric Allergologists and Immunologists of Russia (APAIR) based on the 2021 consensus document, with the necessary data updates.

1. Noon L. Prophylactic inoculations against hay fever. Lancet. 1911; 1: 1572–1573.

2. Cooke RA. The treatment of hay fever by active immunization. Laryngoscope. 1914; 25: 108–112.

3. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet. 1911; 178: 814–817.

4. Meyer-Pittroff R, Behrendt H, Ring J. Specific immuno-modulation and therapy by means of high pressure treated allergens. High Pressure Research. 2007; 27 (1): 63–67.

5. Воробьева ОВ, Гущин ИС. Исторические предпосылки создания метода аллерген-специфической иммунотерапии (К 100-летию открытия). Российский аллергологический журнал. 2010; 5: 17–28. [Vorobjova OV, Gushchin IS. Istoricheskie predposylki sozdaniya metoda allergen-specificheskoj immunoterapii (K 100-letiyu otkrytiya). Rossijskij allergologicheskij zhurnal. 2010; 5: 17–28. (In Russ.)

6. Gushchin IS, Kurbacheva OM. Allergiya i allergen-specificheskaya immunoterapiya. M.: Farmarus Print Media. 2010; 228: 16. (In Russ.)

7. Sahiner UM, Giovannini M, Escribese MM et al. Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation. J Pers Med. 2023; 13 (5): 845. https://doi.org/10.3390/jpm13050845.

8. Mitsias D, Xepapadaki P, Makris M, Papadopoulos N. Immunotherapy in allergic diseases — improved understanding and innovation for enhanced effectiveness. Curr Opin Immunol. 2020; 66: 1–8. https://doi.org/10.1016/j.coi.2020.02.005.

9. Vishneva EA, Namazova-Baranova LS, Alekseeva AA et al. Allergen-spetsificheskaya immunoterapiya u detei: sovremennoe sostoyanie voprosa. Pediatricheskaya farmakologiya. 2016; 13 (4): 404–408. (In Russ.)

10. Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J. Allergy Clin. Immunol. 2017; 140 (6): 1485–1498. https://doi.org/10.1016/j.jaci.2017.10.010.

11. Alvaro-Lozano M, Akdis CA, Akdis M et al. EAACI Allergen Immunotherapy User’s Guide. Pediatr Allergy Immunol. 2020; 25 (25): 1–101. https://doi.org/10.1111/pai.13189.

12. Pavón-Romero GF, Parra-Vargas MI, Ramírez-Jiménez F et al. Allergen Immunotherapy: Current and Future Trends. Cells. 2022; 11 (2): 212. https://doi.org/10.3390/cells11020212.

13. Yu JC, Khodadadi H, Malik A et al. Innate Immunity of Neonates and Infants. Front Immunol. 2018; 9: 1759. https://doi.org/10.3389/ fimmu.2018.01759.

14. Belderbos M, Levy O, Bont L. Neonatal innate immunity in allergy development. Curr Opin Pediatr. 2009; 21 (6): 762–769. https://doi.org/10.1097/MOP.0b013e3283325e3a.

15. Zielen S, Devillier P, Heinrich J et al. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. Allergy. 2018; 73 (1): 165–177. https://doi.org/10.1111/all.13213.

16. Matveeva LP, Ermakova LA. Ekspertiza lecheniya pollinoza u detej allergoidami i allergenami. Problemy ekspertizy v medicine. 2006; 3: 42–44. (In Russ.)

17. Barnes C, Portnoy JM, Ciaccio CE, Pacheco F. A comparison of subject room dust with home vacuum dust for evaluation of dustborne aeroallergens. Ann Allergy Asthma Immunol. 2013; 110 (5): 375–379. https://doi.org/10.1016/j.anai.2013.02.010.

18. Mattsson L, Lundgren T, Everberg H et al. Prostatic kallikrein: a new major dog allergen. J Allergy Clin Immunol. 2009; 123 (2): 362–368. https://doi.org/10.1016/j.jaci.2008.11.021.

19. Van Ree R, Chapman MD, Ferreira F, et al. The CREATE Project: Development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy: European Journal of Allergy and Clinical Immunology. 2008; 63 (3): 310–326. https://doi.org/10.1111/j.1398-9995.2007.01612.x.

20. Larenas-Linnemann D, Cox LS. Immunotherapy and Allergy Diagnostics Committee of the American Academy of Allergy, Asthma and Immunology. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol. 2008; 100 (2): 137–145. https://doi.org/10.1016/S1081-1206(10)60422-X.

21. Gosudarstvennaya farmakopeya. XIII izd. OFS.1.7.1.0001.15. Allergeny. Veb-resurs: https://pharmacopoeia.ru/ofs-1-7-1-0001-15-allergeny/#%D0%98%D0%A1%D0%9F%D0%AB%D0%A2%D0%90%D0%9D%D0%98%D0%AF. Vremya dostupa 08.06.2023. (In Russ.)

22. Lund K, Kito H, Skydtsgaard MB et al. The Importance of Tablet Formulation on Allergen Release Kinetics and Efficiency: Comparison of Freeze-dried and Compressed Grass Pollen Sublingual Allergy Immunotherapy Tablet Formulations. Clin Ther. 2019; 41 (4): 742–753. https://doi.org/10.1016/j.clinthera.2019.02.008.

23. Wahn U, Bachert C, Heinrich J et al. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2019; 74 (3): 594–604. https://doi.org/10.1111/all.13598.

24. Gangl K, Niederberger V, Valenta R. Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology. 2013; 43 (11): 1202–1216. https://doi.org/10.1111/cea.12128.

25. Gunawardana NC, Durham SR. New approaches to allergen immunotherapy. Ann Allergy Asthma Immunol. 2018; 121 (3): 293–305. https://doi.org/10.1016/j.anai.2018.07.014.

26. Ring J, Gutermuth J. 100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). Allergy. 2011; 66 (6): 713–724. https://doi.org/10.1111/j.1398-9995.2010.02541.x.

27. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol. 2007; 119: 826–830.

28. Riabova K, Karsonova AV, van Hage M, et al. Molecular Allergen-Specific IgE Recognition Profiles and Cumulative Specific IgE Levels Associated with Phenotypes of Cat Allergy. Int J Mol Sci. 2022; 23 (13): 6984. Published 2022 Jun 23. https://doi.org/10.3390/ijms23136984.

29. Ding B, Lai Y, Lu Y. Combined application of dupilumab and mite allergen-specific immunotherapy in children with moderate to severe atopic dermatitis. Allergol Immunopathol (Madr). 2023; 51 (2): 184–190. Published 2023 Mar 1. https://doi.org/10.15586/aei.v51i2.778.

30. Casale TB, Busse WW, Kline JN et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006; 117: 134–140.

31. Rodríguez Del Río P, Vidal C, Just J, et al. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment. Pediatr Allergy Immunol. 2017; 28 (1): 60–70. https://doi.org/10.1111/pai.12660.

32. Calderón MA, Vidal C, Rodríguez Del Río P, et al. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment. Allergy. 2017; 72 (3): 462–472. https://doi.org/10.1111/all.13066.

33. Calderón MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012; 67 (3): 302–311. https://doi.org/10.1111/j.1398-9995.2011.02761.x.

34. Di Bona D, Magistà S, Masciopinto L, et al. Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study. Respir Med. 2020; 161: 105843. https://doi.org/10.1016/j.rmed.2019.105843.

35. Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014; 23 (8): 282–319. https://doi.org/10.1007/s40629-014-0032-2.

36. Sánchez-Borges M, Bernstein DI, Calabria C. Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors. Immunol Allergy Clin North Am. 2020; 40 (1): 25–39. https://doi.org/10.1016/j.iac.2019.09.001.

37. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018; 73 (4): 765–798. https://doi.org/10.1111/all.13317.

38. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011; 127 (1): 1–55. https://doi.org/10.1016/j.jaci.2010.09.034.

39. Pitsios C, Demoly P, Bilò MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy. 2015; 70 (8): 897–909. https://doi.org/10.1111/all.12638.

40. Pitsios C, Tsoumani M., Bilò MB, et al. Contraindications to immunotherapy: a global approach. Clin Transl Allergy. 2019; 9: 45. https://doi.org/10.1186/s13601-019-0285-4.

41. Bousquet J, Pfaar O, Togias A, et al. 2019 ARIA Care pathways for allergen immunotherapy. Allergy. 2019; 74 (11): 2087–2102. https://doi.org/10.1111/all.13805.

42. Agache I, Lau S, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019; 74 (5): 855–873. https://doi.org/10.1111/all.13749.

43. Pfaar O, Ankermann T, Augustin M, et al. Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K Guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), Medical Association of German Allergologists (AeDA), Austrian Society of Al lergology and Immunology (ÖGAI), Swiss Society for Allergology and Immunology (SSAI), German Dermatological Society (DDG), German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German Respiratory Society (DGP), German Professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, Sleep and Respiratory Physicians (BdP), Professional Association of German Dermatologists (BVDD). Allergol Select. 2022; 6: 67–232. https://doi.org/10.5414/ALX02331E.

44. Ferrando M, Racca F, Madeira LNG, et al. A critical appraisal on AIT in childhood asthma. Clin Mol Allergy. 2018; 16: 6. https:// doi.org/10.1186/s12948-018-0085-8.

45. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010; 125 (3): 569–574, 574.e1–574.e7. https://doi.org/10.1016/j.jaci.2009.10.060.

46. Iemoli E, Borgonovo L, Fusi A, et al. Sublingual allergen immunotherapy in HIV-positive patients. Allergy. 2016; 71: 412– 415. https://doi.org/10.1111/all.12713.

47. Linneberg A, Madsen F, Skaaby T. Allergen-specific immunotherapy and risk of autoimmune disease. Curr Opin Allergy Clin Immunol. 2012; 12 (6): 635–639. https://doi.org/10.1097/ACI.0b013e3283588c8d.

48. Wollenberg A, Barbarot S, Bieber T, et al. European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018; 32 (6): 850–878. https://doi.org/10.1111/jdv.14888.

49. Egan M, Atkins D. What Is the Relationship Between Eosinophilic Esophagitis (EoE) and Aeroallergens? Implications for Allergen Immunotherapy. Curr Allergy Asthma Rep. 2018; 18 (8): 43. https://doi.org/10.1007/s11882-018-0798-2.

50. Wang C, Bao Y, Chen J, et al. Chinese Society of Allergy (CSA) and Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G). Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update. Allergy Asthma Immunol Res. 2022; 14 (6): 604–652. https://doi.org/10.4168/aair.2022.14.6.604.

51. Gao Y, Lin X, Ma J, et al. Enhanced Efficacy of Dust Mite Sublingual Immunotherapy in Low-Response Allergic Rhinitis Patients after Dose Increment at 6 Months: A Prospective Study. International archives of allergy and immunology. 2020; 181 (4): 311–319. https://doi.org/10.1159/000505746.

52. Chen S, Zheng Y, Chen B, et al. Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens. Int Arch Allergy Immunol. 2019; 178 (2): 201–210. https://doi.org/10.1159/000494389.

53. Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020; 9: CD011293. https://doi.org/10.1002/14651858.CD011293.pub3.

54. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database of Systematic Reviews. 2010; (12). https://doi.org/10.1002/14651858.CD002893.pub2.

55. Klinicheskie rekomendacii. Atopicheskij dermatit. 2021. https://cr.minzdrav.gov.ru/recomend/265_2. Vremya dostupa 18.06.2023 (In Russ.)

56. Lee J, Lee H, Noh S, et al. Retrospective Analysis on the Effects of House Dust Mite Specific Immunotherapy for More Than 3 Years in Atopic Dermatitis. Yonsei Med J. 2016; 57 (2): 393–398. https://doi.org/10.3349/ymj.2016.57.2.393.

57. Liu L, Chen J, Xu J, et al. Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study. Artif Cells Nanomed Biotechnol. 2019; 47 (1): 3540–3547. https://doi.org/10.1080/21691401.2019.1640709.

58. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. Journal of Allergy and Clinical Immunology. 2010; 126 (5): 969–975. https://doi.org/10.1016/j.jaci.2010.08.030.

59. Trebuchon F, Lhéritier-Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy. 2014; 4: 15. https://doi.org/10.1186/2045-7022-4-15.

60. Demoly P, Meziane L, LeGall M, et al. Safety and tolerability of house dust mite tablets in sublingual immunotherapy. J Allergy Clin Immunol. 2008; 121: S128.

61. Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014; 134: 568–575.

62. Mösges R, Ritter B, Kayoko G, Passali D, Allekotte S. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais tablets. Acta Dermatovenerol Alp Pannonica Adriat. 2010 Oct; 19 (3): 3–10.

63. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma.CochraneAirwaysGroup,ed.Cochrane Database of Systematic Reviews. Published on line August 4, 2010. https://doi.org/10.1002/14651858.CD001186.pub2.

64. Gajduk IM, Makarova IV, Trusova OV, Brejkin DV, Suhorukova VG, Arakelyan RN, Korostovtsev DS. Allergen-specificheskaya immunoterapiya pyl’cevymi allergoidami u detej. Rossijskij allergologicheskij zhurnal. 2009; 1: 45–50. (In Russ.)

65. Worm M, Rak S, DeBlay F et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: result of a double-blind, placebo-controlledstudy.Clinical and Translational Allergy. 2014; 4: 1–11.

66. Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology. 2009; 123 (1): 160–166.e3. https://doi.org/10.1016/j.jaci.2008.10.009.

67. Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grasssublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass-pollen allergy. J Allergy Clin Immunol. 2018; 141 (2): 529–538.e13. https://doi.org/10.1016/j.jaci.2017.06.014.

68. Nolte H, Bernstein DI, Nelson HS, et al. Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial. J Allergy Clin Immunol Pract. 2020; 8 (7): 2322–2331.e5. https://doi.org/10.1016/j.jaip.2020.03.041.

69. Maloney J, Berman G, Gagnon R, et al. Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous TreatmentIs Well Tolerated. J Allergy Clin Immunol Pract. 2016; 4 (2): 301-309.e2. https://doi.org/10.1016/j.jaip.2015.11.004.

70. Bousquet J, Hejjaoui A, Dhivert H, etal.Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol. 1989; 83 (4): 797–802. https://doi.org/10.1016/0091-6749(89)90017-1.

71. Smolkin YuS, Maksimova AV. Osobennosti profilakticheskoj vakcinacii detej s allergicheskimi zabolevaniyami. Ucheb.-metod. posobie. Moskva. Izd-vo Akademii postdiplomnogo obrazovaniya FGBU FNKC FMBA Rossii, 2020. 52 s. ISBN 978-5-7151-0559-2. (In Russ.)

72. Chen K-W, Zieglmayer P, Zieglmayer R et al. Selection of house dust mite-allergic patients by molecular diagnosis may enhance success of specific immunotherapy. Journal of Allergy and Clinical Immunology. 2019; 143 (3): 1248–1252.

73. Sastre J, Rodrıguez F, Campo P, et al. Adverse reactions to immunotherapy are associated with different patterns of sensitization to grass allergens. Allergy. 2015; 70 (5): 598–600.

74. Shamji MH, Kappen JH, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy. 2017; 72 (8): 1156–1173. https://doi.org/10.1111/all.13138.

75. Barycheva LYU, Dushina LV, Medvedenko YUN. Izmenenie reaktivnosti bazofilov i sinteza specificheskih immunoglobulinov E pod vliyaniem allergen-immunoterapii. Allergologiya i immunologiya v pediatrii. 2020; 1 (64): 15–23. https://doi.org/10.24412/2500-1175-2021-1-15-23. (In Russ.)

76. Chastnaya allergologiya. Pod red. Ado A. D. M.: «Medicina », 1976. 512 s. (In Russ.)

77. Pfaar O, Demoly P, Gerth van Wijk R,et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014; 69 (7): 854–867.

78. Taktika diagnostiki i lecheniya allergicheskih zabolevanij i immunodeficitov: prakticheskoe rukovodstvo / pod red. R. M. Haitova. — M.: GEOTAR-Media, 2019. — 152 s. https://doi.org/10.33029/9704-5200-4-TER-2019-1-152. (In Russ.)

79. Bae JM, Choi YY, Park CO, et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: asystematic review and meta- analysis of randomized controlled trials. J Allergy Clin Immunol. 2013; 132: 110–117. https://doi.org/10.1016/j.jaci.2013.02.044.

80. Traidl S, Werfel T. Allergen immunotherapy for atopic dermatitis. Hautarzt. 2021; 72 (12): 1103–1112. https://doi.org/10.1007/s00105-021-04909-y.

81. Valera CP, Coelho EB, Galvao CES, et al. Efficacy of House Dust Mite Sublingual Immunotherapy in Patients with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial Randomized Controlled Trial. J Allergy Clin Immunol Pract. 2022; 10 (2): 539–549.e7. https://doi.org/10.1016/j.jaip.2021.10.060.

82. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005; 116 (5): 1073–1079. https://doi.org/10.1016/j.jaci.2005.08.027.

83. Romantsik O, Tosca MA, Zappettini S, Calevo MG. Oral and sublingual immunotherapy for egg allergy (Review). Cochrane Database Syst Rev. 2018; (4): CD010638.

84. Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI guidelines on allergen immunotherapy: IgE mediated food allergy. Allergy. 2018; 73: 799–815.

85. AAAAI current status of oral immunotherapy (ICU) for the treatment of food allergies. [accessed April 1, 2020; available on the Internet: https://www.aaaai.org/conditions-and-treatments/library/allergy-library/oit.

86. Virchow JC, Backer V, Kuna P, et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma. JAMA. 2016; 315 (16): 1715. https://doi.org/10.1001/jama.2016.3964.

87. Wang L, Wang C, Lou H, et al. Antihistamine premedication improves safety and efficacy of allergen immunotherapy. Ann Allergy Asthma Immunol. 2021; 127 (3): 363–371.

88. Lee TH, Chan JKC, Lau PC, et al. Peanut allergy and oral immunotherapy. Hong Kong Med J. 2019; 25 (3): 228–234. https://doi.org/10.12809/hkmj187743.